末梢性T細胞リンパ腫の世界市場レポート 2025年

末梢性T細胞リンパ腫市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR5.6％で7億8,000万米ドルに成長します。予測期間の成長は、標的療法の進歩、個別化医療の採用拡大、免疫療法アプリケーションの拡大、革新的薬剤の強固なパイプライン、新興市場における医療投資の増加、患者アクセスプログラムの成長、診断における人工知能の統合、希少疾病用医薬品に対する規制上の優遇措置、併用療法への注目の高まりなどに起因すると考えられます。この時期の主な動向としては、新規生物製剤の開発、遺伝子編集技術の発展、リキッドバイオプシー診断の採用、AIを活用した治療計画、CAR-T細胞療法の革新、次世代シーケンシングの進展、ドラッグデリバリーへのナノテクノロジーの活用、個別化ワクチンの開発、二重特異性抗体の出現、臨床試験プロセスの自動化などが挙げられます。

リンパ腫の罹患率の上昇が末梢性T細胞リンパ腫（PTCL）市場の成長を牽引すると予想されます。リンパ腫は、身体の免疫系の重要な部分であるリンパ系から発生するがんの一種です。リンパ腫の高い発生率は、遺伝的素因、環境暴露、エプスタイン・バー・ウイルスなどのウイルス感染、免疫不全状態、喫煙や肥満などのライフスタイル要因と関連しています。末梢性T細胞リンパ腫は、成熟T細胞から発生することによりリンパ腫の進行に寄与し、他のリンパ腫サブタイプと比較して、攻撃的な疾患行動、免疫系の機能不全、および低い治療反応性をもたらします。例えば、米国がん協会のFacts and Figuresによると、2023年と2024年の非ホジキンリンパ腫の新規症例数は80,550例と推定されています。その結果、リンパ腫の罹患率の高さがPTCL市場の拡大に拍車をかけています。

PTCL市場の主要企業は、治療効果を高め患者の転帰を改善するために、ジヒドロ葉酸還元酵素阻害剤などの革新的治療法の開発を優先しています。これらの阻害剤は、DNA合成と細胞複製に不可欠な酵素であるジヒドロ葉酸還元酵素の活性を阻害することで効果を発揮します。例えば、ドイツに本社を置く製薬会社フレゼニウス・カビAGは2024年12月、再発または難治性のPTCL治療薬として、フォロティンのジェネリック医薬品であるプララトレキサート注を発売しました。このイントロダクションの導入により、同社のがん領域のポートフォリオが拡充され、臨床医と患者に高品質で費用対効果の高い治療オプションを提供することになります。この注射剤は、20mg/1mLと40mg/2mLの単回投与バイアルがあり、全奏効率に基づく早期承認を取得しました。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界末梢性T細胞リンパ腫PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
• 最終用途産業の分析
• 世界の末梢性T細胞リンパ腫市場：成長率分析
• 世界の末梢性T細胞リンパ腫市場の実績：規模と成長, 2019-2024
• 世界の末梢性T細胞リンパ腫市場の予測：規模と成長, 2024-2029, 2034F
• 世界末梢性T細胞リンパ腫総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の末梢性T細胞リンパ腫市場：タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 末梢性T細胞リンパ腫特に指定なし（PTCL-NOS）
• 血管免疫芽球性T細胞リンパ腫（AITL）
• 未分化大細胞リンパ腫（ALCL）
• 成人T細胞白血病またはリンパ腫（ATLL）
• 腸症関連T細胞リンパ腫（EATL）
• 肝脾T細胞リンパ腫
• その他のタイプ
• 世界の末梢性T細胞リンパ腫市場治療の種類別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 化学療法
• 標的療法
• 免疫療法
• 幹細胞療法
• 放射線治療
• 世界の末梢性T細胞リンパ腫市場：薬剤クラス別、実績と予測, 2019-2024, 2024-2029F, 2034F
• ヒストン脱アセチル化酵素（HDAC）阻害剤
• モノクローナル抗体
• アルキル化剤
• 代謝拮抗剤
• その他の薬物クラス
• 世界の末梢性T細胞リンパ腫市場：投与経路別、実績と予測, 2019-2024, 2024-2029F, 2034F
• オーラル
• 注射剤
• 世界の末梢性T細胞リンパ腫市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院
• 専門クリニック
• 外来手術センター
• 調査機関
• 世界の末梢性T細胞リンパ腫市場、末梢性T細胞リンパ腫のサブセグメンテーション（特に指定なし、PTCL-NOS）、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮膚PTCL
• 全身性PTCL
• 世界の末梢性T細胞リンパ腫市場血管免疫芽球性T細胞リンパ腫（AITL）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• 古典的なAITL
• バリアントAITL
• 世界の末梢性T細胞リンパ腫市場未分化大細胞リンパ腫（ALCL）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 全身性ALCL
• 皮膚ALCL
• 世界の末梢性T細胞リンパ腫市場成人T細胞白血病またはリンパ腫（ATLL）の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 急性ATLL
• 慢性ATLL
• くすぶるATLL
• リンパ腫型ATLL
• 世界の末梢性T細胞リンパ腫市場腸管症関連T細胞リンパ腫（EATL）のサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• タイプ1 EATL
• タイプ2 EATL
• 世界の末梢性T細胞リンパ腫市場肝脾T細胞リンパ腫の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• 肝臓型
• 脾臓型
• 世界の末梢性T細胞リンパ腫市場、その他のタイプのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 皮下T細胞リンパ腫
• リンパ腫様肉芽腫症

第7章 地域別・国別分析

• 世界の末梢性T細胞リンパ腫市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界の末梢性T細胞リンパ腫市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 末梢性T細胞リンパ腫市場：競合情勢
• 末梢性T細胞リンパ腫市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Eisai Co. Ltd.
• Kyowa Kirin Co. Ltd.
• Takeda Pharmaceutical Company Limited
• BeiGene Ltd.
• Daiichi Sankyo Company Limited
• HUYA Bioscience International LLC
• Zymeworks Inc.
• Genor Biopharma Co. Ltd.
• Kura Oncology Inc.
• Acrotech Biopharma LLC
• Spectrum Pharmaceuticals Inc.
• Verastem Inc.
• Astellas Pharma Inc.
• Autolus Therapeutics plc

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 末梢性T細胞リンパ腫市場2029：新たな機会を提供する国
• 末梢性T細胞リンパ腫市場2029：新たな機会を提供するセグメント
• 末梢性T細胞リンパ腫市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Peripheral T-cell lymphoma (PTCL) is a group of aggressive non-Hodgkin lymphomas that develop from mature T-cells, a type of white blood cell crucial for immune function. PTCL can affect the lymph nodes, spleen, bone marrow, liver, and other organs, with symptoms including swollen lymph nodes, fever, night sweats, unexplained weight loss, skin rashes, and persistent fatigue.

The main types of PTCL include peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL), anaplastic large cell lymphoma (ALCL), adult T-cell leukemia/lymphoma (ATLL), enteropathy-associated T-cell lymphoma (EATL), hepatosplenic T-cell lymphoma, and other subtypes. PTCL-NOS is a cancer originating from mature T-cells that do not fit into specific classifications. Treatment options include chemotherapy, targeted therapy, immunotherapy, stem cell therapy, and radiation therapy. The drugs used are classified into histone deacetylase (HDAC) inhibitors, monoclonal antibodies, alkylating agents, antimetabolites, and other categories. These medications are administered through oral and injectable routes and are utilized by various end users, including hospitals, specialty clinics, ambulatory surgical centers, and research institutes.

The peripheral T-cell lymphoma market research report is one of a series of new reports from The Business Research Company that provides peripheral T-cell lymphoma market statistics, including the peripheral T-cell lymphoma industry global market size, regional shares, competitors with the peripheral T-cell lymphoma market share, detailed peripheral T-cell lymphoma market segments, market trends, and opportunities, and any further data you may need to thrive in the peripheral T-cell lymphoma industry. This peripheral T-cell lymphoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The peripheral T-cell lymphoma market size has grown strongly in recent years. It will grow from 0.59 billion in 2024 to $0.63 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth in the historic period can be attributed to increased awareness of rare lymphomas, the emergence of monoclonal antibodies, early orphan drug designations, advancements in hematologic cancer research, the growing adoption of stem cell transplants, improvements in diagnostic accuracy, the expansion of oncology healthcare infrastructure, and early innovations in immunotherapy.

The peripheral T-cell lymphoma market size is expected to see strong growth in the next few years. It will grow to $0.78 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The growth in the forecast period can be attributed to advancements in targeted therapies, the increasing adoption of personalized medicine, the expansion of immunotherapy applications, a robust pipeline of innovative drugs, rising healthcare investments in emerging markets, the growth of patient access programs, the integration of artificial intelligence in diagnostics, regulatory incentives for orphan drugs, and a growing focus on combination therapies. Key trends during this period include the development of novel biologics, advancements in gene editing technologies, the adoption of liquid biopsy diagnostics, AI-driven treatment planning, innovations in CAR-T cell therapy, progress in next-generation sequencing, the use of nanotechnology for drug delivery, personalized vaccine development, the emergence of bispecific antibodies, and automation in clinical trial processes.

The rising incidence of lymphoma is expected to drive the growth of the peripheral T-cell lymphoma (PTCL) market. Lymphoma is a type of cancer that originates in the lymphatic system, a key part of the body's immune system. The high occurrence of lymphoma is linked to genetic predisposition, environmental exposures, viral infections such as the Epstein-Barr virus, immunodeficiency conditions, and lifestyle factors such as smoking and obesity. Peripheral T-cell lymphoma contributes to lymphoma progression by arising from mature T-cells, leading to aggressive disease behavior, immune system dysfunction, and lower treatment responsiveness compared to other lymphoma subtypes. For example, according to the American Cancer Society's Facts and Figures, the estimated number of new non-Hodgkin lymphoma cases remained at 80,550 in both 2023 and 2024. As a result, the high incidence of lymphoma is fueling the expansion of the PTCL market.

Leading companies in the PTCL market are prioritizing the development of innovative treatments, such as dihydrofolate reductase inhibitors, to enhance treatment effectiveness and improve patient outcomes. These inhibitors work by blocking the activity of dihydrofolate reductase, an enzyme crucial for DNA synthesis and cell replication. For instance, in December 2024, Fresenius Kabi AG, a Germany-based pharmaceutical company, launched Pralatrexate Injection, a generic equivalent to Folotyn, for treating relapsed or refractory PTCL. This introduction expands the company's oncology portfolio, offering clinicians and patients a high-quality, cost-effective treatment option. The injection is available in 20 mg/1 mL and 40 mg/2 mL single-dose vials and received accelerated approval based on overall response rate, with continued approval dependent on confirmatory trials.

In August 2024, Citius Pharmaceuticals Inc., a US-based pharmaceutical company specializing in treatments for relapsed or refractory (r/r) cutaneous T-cell lymphoma (CTCL), merged with TenX Keane Acquisition to establish Citius Oncology Inc. This merger aims to create a standalone oncology-focused company, advancing the commercialization of Lymphir and expanding its oncology pipeline. TenX Keane Acquisition Corp. is a US-based company focused on raising capital through an initial public offering (IPO) to acquire or merge with an existing business.

Major players in the peripheral T-cell lymphoma market are Pfizer Inc., Johnson & Johnson, Bristol Myers Squibb Company, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Eisai Co. Ltd., Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Company Limited, BeiGene Ltd., Daiichi Sankyo Company Limited, HUYA Bioscience International LLC, Zymeworks Inc., Genor Biopharma Co. Ltd., Kura Oncology Inc., Acrotech Biopharma LLC, Spectrum Pharmaceuticals Inc., Verastem Inc., Astellas Pharma Inc., Autolus Therapeutics plc.

North America was the largest region in the peripheral T-cell lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in peripheral T-cell lymphoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the peripheral T-cell lymphoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The peripheral T-cell lymphoma market consists of revenues earned by entities by providing services such as diagnosis and screening services, treatment services, hospital and specialty care services, clinical trials and research services. The market value includes the value of related goods sold by the service provider or included within the service offering. The peripheral T-cell lymphoma market also includes sales of corticosteroids, anthracyclines, vinca alkaloids, and topoisomerase inhibitors. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Peripheral T-Cell Lymphoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on peripheral t-cell lymphoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for peripheral t-cell lymphoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The peripheral t-cell lymphoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Type: Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS); Angioimmunoblastic T- Cell Lymphoma (AITL); Anaplastic Large Cell Lymphoma (ALCL); Adult T- Cell Leukaemia Or Lymphoma (ATLL); Enteropathy-Associated T- Cell Lymphoma ( EATL); Hepatosplenic T- Cell Lymphoma; Other Types
• 2) By Treatment Type: Chemotherapy; Target Therapy; Immunotherapy; Stem Cell Therapy; Radiation Therapy
• 3) By Drug Class: Histone Deacetylase (HDAC) Inhibitors; Monoclonal Antibodies; Alkylating Angents; Antimetabolites; Other Drug Class
• 4) By Route Of Administration: Oral; Injectable
• 5) By End-User: Hospitals; Specialty Clinics; Ambulatory Surgical Center; Research Institute
• Subsegments:
• 1) By Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS): Cutaneous PTCL; Systemic PTCL
• 2) By Angioimmunoblastic T-Cell Lymphoma (AITL): Classical AITL; Variant AITL
• 3) By Anaplastic Large Cell Lymphoma (ALCL): Systemic ALCL; Cutaneous ALCL
• 4) By Adult T-Cell Leukaemia Or Lymphoma (ATLL): Acute ATLL; Chronic ATLL; Smoldering ATLL; Lymphoma Type ATLL
• 5) By Enteropathy-Associated T-Cell Lymphoma (EATL): Type 1 EATL; Type 2 EATL
• 6) By Hepatosplenic T-Cell Lymphoma: Hepatic Type; Splenic Type
• 7) By Other Types: Subcutaneous T-Cell Lymphoma; Lymphomatoid Granulomatosis
• Companies Mentioned:Pfizer Inc.; Johnson & Johnson; Bristol Myers Squibb Company; AstraZeneca plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Peripheral T-Cell Lymphoma Market Characteristics

3. Peripheral T-Cell Lymphoma Market Trends And Strategies

4. Peripheral T-Cell Lymphoma Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Peripheral T-Cell Lymphoma Growth Analysis And Strategic Analysis Framework

• 5.1. Global Peripheral T-Cell Lymphoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Peripheral T-Cell Lymphoma Market Growth Rate Analysis
• 5.4. Global Peripheral T-Cell Lymphoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Peripheral T-Cell Lymphoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Peripheral T-Cell Lymphoma Total Addressable Market (TAM)

6. Peripheral T-Cell Lymphoma Market Segmentation

• 6.1. Global Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS)
• Angioimmunoblastic T- Cell Lymphoma (AITL)
• Anaplastic Large Cell Lymphoma (ALCL)
• Adult T- Cell Leukaemia Or Lymphoma (ATLL)
• Enteropathy-Associated T- Cell Lymphoma ( EATL)
• Hepatosplenic T- Cell Lymphoma
• Other Types
• 6.2. Global Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Chemotherapy
• Target Therapy
• Immunotherapy
• Stem Cell Therapy
• Radiation Therapy
• 6.3. Global Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Histone Deacetylase (HDAC) Inhibitors
• Monoclonal Antibodies
• Alkylating Angents
• Antimetabolites
• Other Drug Class
• 6.4. Global Peripheral T-Cell Lymphoma Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Injectable
• 6.5. Global Peripheral T-Cell Lymphoma Market, Segmentation By End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Specialty Clinics
• Ambulatory Surgical Center
• Research Institute
• 6.6. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Peripheral T-Cell Lymphoma Not Otherwise Specified (PTCL-NOS), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cutaneous PTCL
• Systemic PTCL
• 6.7. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Angioimmunoblastic T-Cell Lymphoma (AITL), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Classical AITL
• Variant AITL
• 6.8. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Anaplastic Large Cell Lymphoma (ALCL), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Systemic ALCL
• Cutaneous ALCL
• 6.9. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Adult T-Cell Leukaemia Or Lymphoma (ATLL), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Acute ATLL
• Chronic ATLL
• Smoldering ATLL
• Lymphoma Type ATLL
• 6.10. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Enteropathy-Associated T-Cell Lymphoma (EATL), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Type 1 EATL
• Type 2 EATL
• 6.11. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Hepatosplenic T-Cell Lymphoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hepatic Type
• Splenic Type
• 6.12. Global Peripheral T-Cell Lymphoma Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Subcutaneous T-Cell Lymphoma
• Lymphomatoid Granulomatosis

7. Peripheral T-Cell Lymphoma Market Regional And Country Analysis

• 7.1. Global Peripheral T-Cell Lymphoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Peripheral T-Cell Lymphoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Peripheral T-Cell Lymphoma Market

• 8.1. Asia-Pacific Peripheral T-Cell Lymphoma Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Peripheral T-Cell Lymphoma Market

• 9.1. China Peripheral T-Cell Lymphoma Market Overview
• 9.2. China Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Peripheral T-Cell Lymphoma Market

• 10.1. India Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Peripheral T-Cell Lymphoma Market

• 11.1. Japan Peripheral T-Cell Lymphoma Market Overview
• 11.2. Japan Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Peripheral T-Cell Lymphoma Market

• 12.1. Australia Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Peripheral T-Cell Lymphoma Market

• 13.1. Indonesia Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Peripheral T-Cell Lymphoma Market

• 14.1. South Korea Peripheral T-Cell Lymphoma Market Overview
• 14.2. South Korea Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Peripheral T-Cell Lymphoma Market

• 15.1. Western Europe Peripheral T-Cell Lymphoma Market Overview
• 15.2. Western Europe Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Peripheral T-Cell Lymphoma Market

• 16.1. UK Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Peripheral T-Cell Lymphoma Market

• 17.1. Germany Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Peripheral T-Cell Lymphoma Market

• 18.1. France Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Peripheral T-Cell Lymphoma Market

• 19.1. Italy Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Peripheral T-Cell Lymphoma Market

• 20.1. Spain Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Peripheral T-Cell Lymphoma Market

• 21.1. Eastern Europe Peripheral T-Cell Lymphoma Market Overview
• 21.2. Eastern Europe Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Peripheral T-Cell Lymphoma Market

• 22.1. Russia Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Peripheral T-Cell Lymphoma Market

• 23.1. North America Peripheral T-Cell Lymphoma Market Overview
• 23.2. North America Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Peripheral T-Cell Lymphoma Market

• 24.1. USA Peripheral T-Cell Lymphoma Market Overview
• 24.2. USA Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Peripheral T-Cell Lymphoma Market

• 25.1. Canada Peripheral T-Cell Lymphoma Market Overview
• 25.2. Canada Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Peripheral T-Cell Lymphoma Market

• 26.1. South America Peripheral T-Cell Lymphoma Market Overview
• 26.2. South America Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Peripheral T-Cell Lymphoma Market

• 27.1. Brazil Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Peripheral T-Cell Lymphoma Market

• 28.1. Middle East Peripheral T-Cell Lymphoma Market Overview
• 28.2. Middle East Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Peripheral T-Cell Lymphoma Market

• 29.1. Africa Peripheral T-Cell Lymphoma Market Overview
• 29.2. Africa Peripheral T-Cell Lymphoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Peripheral T-Cell Lymphoma Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Peripheral T-Cell Lymphoma Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Peripheral T-Cell Lymphoma Market Competitive Landscape And Company Profiles

• 30.1. Peripheral T-Cell Lymphoma Market Competitive Landscape
• 30.2. Peripheral T-Cell Lymphoma Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Johnson & Johnson Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Peripheral T-Cell Lymphoma Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Eisai Co. Ltd.
• 31.3. Kyowa Kirin Co. Ltd.
• 31.4. Takeda Pharmaceutical Company Limited
• 31.5. BeiGene Ltd.
• 31.6. Daiichi Sankyo Company Limited
• 31.7. HUYA Bioscience International LLC
• 31.8. Zymeworks Inc.
• 31.9. Genor Biopharma Co. Ltd.
• 31.10. Kura Oncology Inc.
• 31.11. Acrotech Biopharma LLC
• 31.12. Spectrum Pharmaceuticals Inc.
• 31.13. Verastem Inc.
• 31.14. Astellas Pharma Inc.
• 31.15. Autolus Therapeutics plc

32. Global Peripheral T-Cell Lymphoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Peripheral T-Cell Lymphoma Market

34. Recent Developments In The Peripheral T-Cell Lymphoma Market

35. Peripheral T-Cell Lymphoma Market High Potential Countries, Segments and Strategies

• 35.1 Peripheral T-Cell Lymphoma Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Peripheral T-Cell Lymphoma Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Peripheral T-Cell Lymphoma Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer